BEAT® the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs

Pierre Moretti, Darko Skegro, Romain Ollier, Paul Wassmann, Christel Aebischer, Thibault Laurent, Miriam Schmid-Printz, Roberto Giovannini, Stanislas Blein, Martin Bertschinger

BMC Proceedings · 2013 · 30 citations · 0 references

DOIFull text

Open access

Concepts

Abstract

Background The binding of two biological targets with a single IgGbased molecule is thought to be beneficial for clinical efficacy. However the technological challenges for the development of a bispecific platform are numerous. While correct pairing of heterologous heavy and light chains (Hc and Lc) can be achieved by engineering native IgG scaffolds, crucial properties such as thermostability, effector function and low immunogenicity should be maintained [1]. The molecule has to be expressed at industrially relevant levels with a minimum fraction of contaminants and a scalable purification approach is needed to isolate the product from potentially complex mixtures. This article introduces a novel bispecific platform based on the proprietary BEAT technology (Bispecific Engagement by Antibodies based on the T cell receptor) developed by Glenmark.